Kevin Litcofsky

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial

Barbara McGovern, Christopher B. Ford, Matthew R. Henn et al. · Clinical Infectious Diseases · 2020 · 150 citations · Full text

Iterative plug-and-play methodology for constructing and modifying synthetic gene networks

Kevin Litcofsky, Raffi Afeyan, Russell J. Krom et al. · Nature Methods · 2012 · 94 citations · Full text

Bioinformatics, Engineering, Genetics +15

1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)

Christopher B. Ford, Kevin Litcofsky, Barbara McGovern et al. · Open Forum Infectious Diseases · 2019 · 11 citations · Full text

Dysbiosis, Microbial Pathogens, Antibiotic Resistance +20

Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent<i>Clostridioides difficile</i>Infection

Timothy J. Straub, Mary‐Jane Lombardo, Jessica A. Bryant et al. · Clinical Infectious Diseases · 2023 · 11 citations · Full text